{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:38:07Z","timestamp":1792719487285,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP50773496"],"award-info":[{"award-number":["JP50773496"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16445-w","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:55:46Z","timestamp":1785138946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuri","family":"Aoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kamima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tokumasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyon","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"31","key":"16445_CR1","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1200\/JCO.2015.61.1301","volume":"33","author":"DR Murphy","year":"2015","unstructured":"Murphy DR, Wu L, Thomas EJ, Forjuoh SN, Meyer AN, Singh H. Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial. J Clin Oncol. 2015;33(31):3560\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.61.1301. Epub 2015 Aug 24.","journal-title":"J Clin Oncol"},{"issue":"9","key":"16445_CR2","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","volume":"17","author":"K Furuse","year":"1999","unstructured":"Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non\u2013small-cell lung cancer. J Clin Oncol. 1999;17(9):2692\u20139. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2692.","journal-title":"J Clin Oncol"},{"issue":"20","key":"16445_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937. Epub 2017 Sep 8.","journal-title":"N Engl J Med"},{"issue":"12","key":"16445_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planleftd D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308. Epub 2022 Feb 2.","journal-title":"J Clin Oncol"},{"key":"16445_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","volume":"146","author":"HA Jung","year":"2020","unstructured":"Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2020;146:23\u20139. Epub 2020 May 31.","journal-title":"Lung Cancer"},{"key":"16445_CR6","first-page":"57","volume":"37","author":"Y Takeda","year":"2022","unstructured":"Takeda Y, Kusaba Y, Tsukita Y, Uemura Y, Miyauchi E, Yamamoto T, et al. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: a multicenter retrospective cohort study. Clin Transl Radiat Oncol. 2022;37:57\u201363. eCollection 2022 Nov.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"22","key":"16445_CR7","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/1759-7714.14667","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zhao JJ, Soon YY, Wong A, Aminkeng F, Ang Y, et al. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Thorac Cancer. 2022;13(22):3152\u201361. https:\/\/doi.org\/10.1111\/1759-7714.14667 . Epub 2022 Sep 30.","journal-title":"Thorac Cancer"},{"issue":"3","key":"16445_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4143\/crt.2023.1014","volume":"56","author":"JY Jang","year":"2024","unstructured":"Jang JY, Song SY, Shin YS, Kim HU, Choi EK, Kim SW, et al. Contribution of enhanced locoregional control to improved overall survival with consolidative durvalumab after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: insights from real-world data. Cancer Res Treat. 2024;56(3):785\u201394. https:\/\/doi.org\/10.4143\/crt.2023.1014. Epub 2024 Jan 16.","journal-title":"Cancer Res Treat"},{"key":"16445_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2340\/1651-226X.2025.42384","volume":"64","author":"RH Stoffers","year":"2025","unstructured":"Stoffers RH, Niezink AGH, Chouvalova O, Ubbels JF, Woltman-van Iersel M, Hiltermann TJN, et al. Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy. Acta Oncol. 2025;64:267\u201375. https:\/\/doi.org\/10.2340\/1651-226X.2025.42384.","journal-title":"Acta Oncol"},{"key":"16445_CR10","doi-asserted-by":"publisher","unstructured":"Kamima T, Iino M, Sakai R, Ito Y, Sakae T, Moriya S et al. Evaluation of the four-dimensional motion of lung tumors during end-exhalation breath-hold conditions using volumetric cine computed tomography images. Radiother Oncol 2023 May:182:109573. https:\/\/doi.org\/10.1016\/j.radonc.2023.109573","DOI":"10.1016\/j.radonc.2023.109573"},{"key":"16445_CR11","unstructured":"U.S. Department of health and human services, national institutes of health, national cancer institute. Common terminology criteria for adverse events (CTCAE) version 5.0. Published November 27, 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed 30 Jan 2026."},{"issue":"1","key":"16445_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1186\/s12885-023-11472-3","volume":"23","author":"Z Yang","year":"2023","unstructured":"Yang Z, Zhong W, Luo Y, Wu C. The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2023;23(1):962. https:\/\/doi.org\/10.1186\/s12885-023-11472-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"16445_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244 . Epub 2012 Dec 3.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"16445_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ijrobp.2023.09.050","volume":"118","author":"DM Edwards","year":"2024","unstructured":"Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, et al. Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2024;118(4):963\u201370. Epub 2023 Oct 2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16445_CR15","doi-asserted-by":"publisher","unstructured":"Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T et al. eCollection. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Ther Adv Med Oncol. 2022 Dec 18:14:17588359221142786. https:\/\/doi.org\/10.1177\/17588359221142786. 2022.","DOI":"10.1177\/17588359221142786"},{"issue":"1","key":"16445_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13014-021-01930-2","volume":"16","author":"JY Jang","year":"2021","unstructured":"Jang JY, Kim SS, Song SY, Kim YJ, Kim SW, Choi EK. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study. Radiat Oncol. 2021;16(1):231. https:\/\/doi.org\/10.1186\/s13014-021-01930-2.","journal-title":"Radiat Oncol"},{"issue":"5","key":"16445_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/1759-7714.13394","volume":"11","author":"Y Miura","year":"2020","unstructured":"Miura Y, Mouri A, Kaira K, Yamaguchi O, Shiono A, Hashimoto K, et al. Chemoradiotherapy followed by durvalumab in patientswith unresectable advanced non-small cell lung cancer:management of adverse events. Thorac Cancer. 2020;11(5):1280\u20137. https:\/\/doi.org\/10.1111\/1759-7714.13394. Epub 2020 Mar 11.","journal-title":"Thorac Cancer"},{"key":"16445_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ctro.2020.05.006","volume":"23","author":"S Saito","year":"2020","unstructured":"Saito S, Abe T, Kobayashi N, Aoshika T, Ryuno Y, Igari M, et al. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. Clin Transl Radiat Oncol. 2020;23:85\u20138. https:\/\/doi.org\/10.1016\/j.ctro.2020.05.006.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"16445_CR19","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.21037\/jtd-20-1792","volume":"12","author":"C Hassanzadeh","year":"2020","unstructured":"Hassanzadeh C, Sita T, Savoor R, Samson PP, Bradley J, Gentile M, et al. Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. J Thorac Dis. 2020;12(11):6690\u2013700. https:\/\/doi.org\/10.21037\/jtd-20-1792.","journal-title":"J Thorac Dis"},{"key":"16445_CR20","doi-asserted-by":"publisher","unstructured":"Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H et al. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiother Oncol 2021 Jul:160:266\u201372. https:\/\/doi.org\/10.1016\/j.radonc.2021.05.016. Epub 2021 May 21.","DOI":"10.1016\/j.radonc.2021.05.016"},{"issue":"2","key":"16445_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10637-021-01191-6","volume":"40","author":"A Nishimura","year":"2022","unstructured":"Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, et al. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. Invest New Drugs. 2022;40(2):403\u201310. https:\/\/doi.org\/10.1007\/s10637-021-01191-6 . Epub 2021 Oct 11.","journal-title":"Invest New Drugs"},{"key":"16445_CR22","doi-asserted-by":"publisher","unstructured":"Kakiuchi Y, Saruwatari K, Tokito T, Iriki T, Iwakawa J, Sakata Y et al. Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer. Lung Cancer 2025 Jun:204:108578. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108578. Epub 2025 May 6.","DOI":"10.1016\/j.lungcan.2025.108578"},{"issue":"4","key":"16445_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ijrobp.2024.01.217","volume":"119","author":"C Han","year":"2024","unstructured":"Han C, Qiu J, Bai L, Liu T, Chen J, Wang H, Dang J. Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2024;119(4):1179\u2013207. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.217. Epub 2024 Feb 13.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"16445_CR24","first-page":"339","volume":"44","author":"Y Yoshioka","year":"1999","unstructured":"Yoshioka Y, Hasegawa M, Sasaoka M, Sawa T, Inomoto T. Predictors of radiation pneumonitis after thoracic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1999;44(2):339\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"16445_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","volume":"71","author":"G Rodrigues","year":"2004","unstructured":"Rodrigues G, Lock M, D\u2019Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer\u2013a systematic review. Radiother Oncol. 2004;71(2):127\u201338. https:\/\/doi.org\/10.1016\/j.radonc.2004.02.015.","journal-title":"Radiother Oncol"},{"issue":"5","key":"16445_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.ijrobp.2021.07.1691","volume":"111","author":"MR McFarlane","year":"2021","unstructured":"McFarlane MR, Hochstedler KA, Laucis AM, Sun Y, Chowdhury A, Matuszak MM, et al. Predictors of pneumonitis after conventionally fractionated radiotherapy for locally advanced lung cancer. Int J Radiat Oncol Biol Phys. 2021;111(5):1176\u201385. Epub 2021 Jul 24.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"16445_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00432-012-1284-1","volume":"138","author":"XJ Zhang","year":"2012","unstructured":"Zhang XJ, Sun JG, Sun J, Ming H, Wang XX, Wu L, et al. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol. 2012;138(12):2103\u201316. https:\/\/doi.org\/10.1007\/s00432-012-1284-1 . Epub 2012 Jul 29.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"16445_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","volume":"22","author":"T Shintani","year":"2021","unstructured":"Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer. 2021;22(5):401\u201310. Epub 2021 Feb 4.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"16445_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/jjco\/hyad158","volume":"54","author":"M Masuo","year":"2024","unstructured":"Masuo M, Shinohara E, Kitano M, Maruta R, Chonabayashi S, Endo S, et al. A comparison of the incidence of \u2265\u2009grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy. Jpn J Clin Oncol. 2024;54(3):312\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyad158.","journal-title":"Jpn J Clin Oncol"},{"issue":"1173","key":"16445_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/bjr\/tqaf133","volume":"98","author":"S Appel","year":"2025","unstructured":"Appel S, Wilk L, Saad A, Urban D, Sorotsky H, Kalmanovitz G, et al. Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer, predictors and effect on survival. Br J Radiol. 2025;98(1173):1436\u201345. https:\/\/doi.org\/10.1093\/bjr\/tqaf133.","journal-title":"Br J Radiol"},{"key":"16445_CR31","doi-asserted-by":"publisher","unstructured":"Jia R, Li L, Liu X, Zhang J, Li S, Wang Z et al. Improper lung volume-dose parameters are risk factors for acute fatal radiation pneumonitis among esophageal cancer patients receiving chemoradiotherapy: a case-control study. Front Oncol. 2025;15:1535676. https:\/\/doi.org\/10.3389\/fonc.2025.1535676. eCollection 2025.","DOI":"10.3389\/fonc.2025.1535676"},{"issue":"8","key":"16445_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","volume":"10","author":"SG Chun","year":"2024","unstructured":"Chun SG, Hu C, Komaki RU, Timmerman RD, Schild SE, Bogart JA, et al. Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2024;10(8):1111\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1841.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16445-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:01:44Z","timestamp":1792717304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16445-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16445"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16445-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of The Cancer Institute Hospital of Japanese Foundation for Cancer Research (Approval No. 2021-GA-1056). The study was conducted in accordance with the Declaration of Helsinki. Due to the retrospective nature of the study and the use of de-identified clinical data, the requirement for written informed consent was waived. An opt-out approach was implemented via institutional public disclosure.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ryo Ariyasu has received honoraria from AstraZeneca, Chugai Pharmaceutical, MSD, ONO Pharmaceutical, Bristol Myers Squibb, and Novartis. Makoto Nishio has received honoraria from Novartis, ONO Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, TAIHO Pharmaceutical, Eli Lilly, Pfizer, Daiichi-Sankyo, Merck Sharp & Dohme, AbbVie, Takeda Pharmaceutical, Boehringer Ingelheim, Nippon Kayaku, Merck BioPharma, Janssen, and AstraZeneca. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1280"}}